Most Recent

image: Control ALT, Delete Cancer

Control ALT, Delete Cancer

By , and | April 1, 2015

Treating cancer by shutting down the alternative lengthening of telomeres (ALT) pathway

1 Comment

image: Enhanced Enhancers

Enhanced Enhancers

By | November 1, 2014

Treating cancer by shutting down the alternative lengthening of telomeres (ALT) pathway

0 Comments

image: Remaking Nature

Remaking Nature

By | August 1, 2013

Treating cancer by shutting down the alternative lengthening of telomeres (ALT) pathway

6 Comments

image: Defending Against Plagiarism

Defending Against Plagiarism

By | June 1, 2013

Treating cancer by shutting down the alternative lengthening of telomeres (ALT) pathway

5 Comments

image: Bring On the Transparency Index

Bring On the Transparency Index

By | August 1, 2012

Treating cancer by shutting down the alternative lengthening of telomeres (ALT) pathway

6 Comments

image: Predatory Publishing

Predatory Publishing

By | August 1, 2012

Treating cancer by shutting down the alternative lengthening of telomeres (ALT) pathway

29 Comments

image: All’s Not Fair in Science and Publishing

All’s Not Fair in Science and Publishing

By | July 1, 2012

Treating cancer by shutting down the alternative lengthening of telomeres (ALT) pathway

72 Comments

image: Avoiding Animal Testing

Avoiding Animal Testing

By | December 1, 2011

Treating cancer by shutting down the alternative lengthening of telomeres (ALT) pathway

82 Comments

image: Vive la Différence

Vive la Différence

By | September 1, 2011

Treating cancer by shutting down the alternative lengthening of telomeres (ALT) pathway

6 Comments

image: Desperately Seeking Radioisotopes

Desperately Seeking Radioisotopes

By | July 1, 2011

Treating cancer by shutting down the alternative lengthening of telomeres (ALT) pathway

21 Comments

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech